Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Briana M. Choi, Rachel B. Abraham, Hala Halawah, Matthias Calamia, Mavis Obeng-Kusi, Neda Alrawashdh, Daniel Arku & Ivo Abraham. (2021) Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities. Journal of Medical Economics 24:sup1, pages 34-41.
Read now
Read now
Jiujie Cui, Xiaochen Zhang, Shuli Qu & Liwei Wang. (2021) Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 691-697.
Read now
Read now
Yazan K. Barqawi, Matthew E. Borrego, Melissa H. Roberts & Ivo Abraham. (2019) Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. Journal of Medical Economics 22:11, pages 1202-1209.
Read now
Read now
Carlo Lazzaro, Carlo Barone, Francesco Caprioni, Stefano Cascinu, Alfredo Falcone, Evaristo Maiello, Michele Milella, Carmine Pinto, Michele Reni & Giampaolo Tortora. (2018) An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert Review of Pharmacoeconomics & Outcomes Research 18:4, pages 435-446.
Read now
Read now
Ali McBride, Machaon Bonafede, Qian Cai, Nicole Princic, Oth Tran, Corey Pelletier, Monika Parisi & Manish Patel. (2017) Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Expert Review of Clinical Pharmacology 10:10, pages 1153-1160.
Read now
Read now
Articles from other publishers (19)
Xiaoting Huang, Dong Lin, Shen Lin, Shaohong Luo, Xiaojia Huang, Yujie Deng, Xiuhua Weng & Pinfang Huang. (2023) Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression. Clinical Breast Cancer 23:5, pages 508-518.
Crossref
Crossref
Keisuke Okuno, Caiming Xu, Silvia Pascual-Sabater, Masanori Tokunaga, Tetsuji Takayama, Haiyong Han, Cristina Fillat, Yusuke Kinugasa & Ajay Goel. (2023) Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma. Biomedicines 11:1, pages 119.
Crossref
Crossref
Keisuke Okuno, Caiming Xu, Silvia Pascual-Sabater, Masanori Tokunaga, Haiyong Han, Cristina Fillat, Yusuke Kinugasa & Ajay Goel. (2022) Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals 15:10, pages 1199.
Crossref
Crossref
Karen MacDonald, Neda Alrawashdh, Ali McBride & Ivo Abraham. (2021) Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. Future Oncology 17:33, pages 4561-4570.
Crossref
Crossref
Aditi A KharatRichard NelsonTrang AuJoseph Biskupiak. (2021) Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials. Journal of Managed Care & Specialty Pharmacy 27:10, pages 1367-1375.
Crossref
Crossref
Gursharan K. Sohi, Jordan Levy, Victoria Delibasic, Laura E. Davis, Alyson L. Mahar, Elmira Amirazodi, Craig C. Earle, Julie Hallet, Ahmed Hammad, Rajan Shah, Nicole Mittmann & Natalie G. Coburn. (2021) The cost of chemotherapy administration: a systematic review and meta-analysis. The European Journal of Health Economics 22:4, pages 605-620.
Crossref
Crossref
Taiga Otsuka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, Futa Koga, Yasunori Kawaguchi, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Yoshinobu Okabe, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Toshihiko Mizuta, Kenji Mitsugi & Norio Ureshino. (2021) A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. International Journal of Clinical Oncology 26:5, pages 941-950.
Crossref
Crossref
Xiangxuan Zhao, Ying Ren & Zaiming Lu. (2020) Potential diagnostic and therapeutic roles of exosomes in pancreatic cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1874:2, pages 188414.
Crossref
Crossref
Bin Wu & Lizheng Shi. (2020) Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Journal of the National Comprehensive Cancer Network 18:11, pages 1528-1536.
Crossref
Crossref
Andrea BullockChristopher G. RowanNina OestreicherHoma YeganegiE. Gabriela Chiorean. (2020) Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy. Journal of Managed Care & Specialty Pharmacy 26:7, pages 872-878.
Crossref
Crossref
Xiuhua Weng, Xiaoting Huang, Hongchao Li, Shen Lin, Xin Rao, Xianzhong Guo & Pinfang Huang. (2020) First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer. American Journal of Clinical Oncology 43:5, pages 340-348.
Crossref
Crossref
Jeung Eun Lee, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song & Seungmin Bang. (2020) Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer. Gut and Liver 14:1, pages 135-143.
Crossref
Crossref
Sung-Hee Jeon & R. Vincent Pohl. (2019) Medical innovation, education, and labor market outcomes of cancer patients. Journal of Health Economics 68, pages 102228.
Crossref
Crossref
Julien Péron, Joris Giai, Delphine Maucort-Boulch & Marc Buyse. (2019) The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma. Pancreas 48:2, pages 275-280.
Crossref
Crossref
Nicolas Williet, Angélique Saint, Anne-Laure Pointet, David Tougeron, Simon Pernot, Astrid Pozet, Dominique Bechade, Isabelle Trouilloud, Nelson Lourenco, Vincent Hautefeuille, Christophe Locher, Jérome Desrame, Pascal Artru, Anne Thirot Bidault, Bertrand Le Roy, Denis Pezet, Jean-Marc Phelip & Julien Taieb. (2019)
Folfirinox
versus
gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
. Therapeutic Advances in Gastroenterology 12, pages 175628481987866.
Crossref
Crossref
Mamoon Ur Rashid, Ishtiaq Hussain, Sundas Jehanzeb, Waqas Ullah, Saeed Ali, Akriti Gupta Jain, Ranjeet Kumar, Neelam Khetpal & Sarfraz Ahmad. 2019. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy
57
85
.
Takeshi Terashima, Tatsuya Yamashita, Akito Sakai, Hajime Ohta, Yoshinobu Hinoue, Daisyu Toya, Hiroshi Kawai, Manabu Yonejima, Takeshi Urabe, Yatsugi Noda, Eishiro Mizukoshi & Shuichi Kaneko. (2018) Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis. Japanese Journal of Clinical Oncology 48:11, pages 966-973.
Crossref
Crossref
Andrew H. Ko. (2017) Clinical Management. The Cancer Journal 23:6, pages 355-361.
Crossref
Crossref
Aurélien Lambert, Céline Gavoille & Thierry Conroy. (2017) Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therapeutic Advances in Gastroenterology 10:8, pages 631-645.
Crossref
Crossref